Display options
Cite
Linder K, Gandhiraj D, Hanmantgad M, et al. Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG. Exp Hematol Oncol. 2016;5:20doi: 10.1186/s40164-016-0051-4.
Linder, K., Gandhiraj, D., Hanmantgad, M., Seiter, K., & Liu, D. (2015). Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG. Experimental hematology & oncology, 520. https://doi.org/10.1186/s40164-016-0051-4
Linder, Katherine, et al. "Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG." Experimental hematology & oncology vol. 5 (2015): 20. doi: https://doi.org/10.1186/s40164-016-0051-4
Linder K, Gandhiraj D, Hanmantgad M, Seiter K, Liu D. Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG. Exp Hematol Oncol. 2016 Jul 26;5:20. doi: 10.1186/s40164-016-0051-4. eCollection 2015. PMID: 27468365; PMCID: PMC4962515.
Copy Download .nbib Format: NLM
Share it on

Exp Hematol Oncol. 2016 Jul 26;5:20. doi: 10.1186/s40164-016-0051-4. eCollection 2015.

Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG.

Experimental hematology & oncology

Katherine Linder, Deepthi Gandhiraj, Madhura Hanmantgad, Karen Seiter, Delong Liu

Affiliations

  1. Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595 USA.

PMID: 27468365 PMCID: PMC4962515 DOI: 10.1186/s40164-016-0051-4

Abstract

BACKGROUND: The current standard of care for relapsed and refractory acute lymphoblastic leukemia (ALL) is combination chemotherapy.

CASE PRESENTATION: We report a case of highly refractory ALL who was treated with blinatumomab. The ALL in this patient relapsed within a month after completion of hyperCVAD regimen and was refractory to high dose mitoxantrone/cytarabine and CLAG regimens.

CONCLUSION: This highly refractory pre-B Ph(-) ALL was induced to complete remission after one course of single agent blinatumomab.

References

  1. Oncology (Williston Park). 2012 Sep;26(9):851-9 - PubMed
  2. Blood. 1987 Apr;69(4):1242-8 - PubMed
  3. Blood. 1991 Dec 1;78(11):2814-22 - PubMed
  4. MAbs. 2014 May-Jun;6(3):728-39 - PubMed
  5. N Engl J Med. 2014 Oct 16;371(16):1507-17 - PubMed
  6. Cancer. 2005 Jul 1;104(1):110-7 - PubMed
  7. J Clin Oncol. 2000 Feb;18(3):547-61 - PubMed
  8. J Hematol Oncol. 2015 Sep 04;8:104 - PubMed
  9. Cancer. 2004 Dec 15;101(12):2788-801 - PubMed
  10. MAbs. 2015;7(3):584-604 - PubMed
  11. Sci Transl Med. 2013 Mar 20;5(177):177ra38 - PubMed
  12. Blood. 2000 Mar 15;95(6):2098-103 - PubMed
  13. N Engl J Med. 2015 Jan 22;372(4):311-9 - PubMed
  14. Leuk Lymphoma. 2002 Feb;43(2):315-25 - PubMed
  15. N Engl J Med. 2011 Aug 25;365(8):725-33 - PubMed
  16. J Hematol Oncol. 2013 Jun 18;6:40 - PubMed
  17. Science. 2008 Aug 15;321(5891):974-7 - PubMed
  18. J Hematol Oncol. 2015 Nov 20;8:129 - PubMed
  19. Leuk Lymphoma. 2000 Sep;39(1-2):121-9 - PubMed
  20. J Hematol Oncol. 2013 Jul 08;6:47 - PubMed
  21. Blood. 2013 Feb 14;121(7):1077-82 - PubMed
  22. J Hematol Oncol. 2015 Aug 01;8:96 - PubMed
  23. Blood. 2007 Oct 1;110(7):2268-75 - PubMed
  24. Sci Transl Med. 2011 Aug 10;3(95):95ra73 - PubMed
  25. Leukemia. 2004 May;18(5):989-97 - PubMed
  26. Cancer. 2013 Mar 15;119(6):1186-94 - PubMed
  27. J Hematol Oncol. 2015 Oct 08;8:111 - PubMed
  28. Lancet Oncol. 2015 Jan;16(1):57-66 - PubMed

Publication Types